Intervention to Increase Screening for Glucocorticoid Induced Diabetes (CDA-GID)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Aim 1: Conduct a single site randomized controlled feasibility trial of a decisional support intervention to reduce ADRLLS by improving providers' adherence to GID prevention measures. Approximately 20 primary care providers (caring for approximately 100 veterans on chronic steroids who have not been screened for diabetes in the last year) will be randomly assigned to receive decisional support for GID prevention measures (automatically-derived orders for hemoglobin A1C, to be co-signed by providers). These providers will be compared with 20 providers (caring for 100 veterans not screened for diabetes in the last year) who are randomly assigned to not receive decisional support for management of GID (i.e. the control group). The trial will be conducted at the VA's Eastern Colorado Health Care System (ECHCS) and will last approximately 6 months. Study administration will be coordinated through the Colorado Research Award Enhancement Program (Colorado REAP).
Aim 1a) Procedural Endpoints: As a feasibility trial, this study includes multiple procedural endpoints, such as provider participation rates, to assess the viability of the intervention, rather than a single primary efficacy outcome measure (for details, pages 6-7).
Aim 1b) Preliminary Estimates of Efficacy: We will determine the Delay Interval-the number of days from when a provider is randomized until the provider orders the GID prevention measure. Use of this continuous measure will maximize the power of this feasibility study, though we will also determine proportions of patients for whom these measures were ordered at six months, so that we may estimate the sample size for a subsequent multi-center randomized control trial.
Aim 1c) Post-trial de-briefing: Using structured interviews, we will examine the opinions of providers after they have participated in the GID feasibility trial, in order to gather additional qualitative data regarding the ADRLL framework and refine the intervention for a subsequent randomized controlled trial. Providers will also complete a brief survey assessing their preference for the intervention.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Liron Caplan
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
- Must be 18-90 years old
- Must be served by the ECHCS VA sytem
- Must have chronic glucocorticoid exposure (greater than or equal to 90 days of oral glucocorticoids)
- Eligible providers will consist of those primary care practitioners within the ECHCS with at least one patient meeting the above criteria. For each veteran, the primary care provider (PCP) will be defined as the patient's current general internal medicine or family practice practitioner. In the rare instance in which the patient has no PCP within the VA system, the specialist with the greatest number of patient encounters during the past 12 months will be eligible for inclusion. For every patient, only one provider will be randomized (to avoid multiple exposure to the intervention for some patients). The consent procedure is described below.
Exclusion Criteria:
- Veterans who have had a hgbA1C test within the previous 12 months will be excluded.
- Providers without eligible patients (described above), will be excluded.
- Providers declining to give consent will be excluded.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Decision Support Intervention
Clinical pharmacists mediated computerized decision support
|
Clinical pharmacists mediated computerized decision support
|
|
Aktiver Komparator: Usual Care
Clinicians' typical approach for GID monitoring
|
clinicians typical apporach for GID monitering
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).
Zeitfenster: 6 MONTHS
|
For follow-up laboratory data within the VA system, adherence will be monitored through prospective accrual of administrative data and review of the medical record.
Results will be reported as the proportion receiving the preventive measure versus time, i.e. with Kaplan-Meier plots.
We will then determine the variance of Delay Interval.
For the preliminary measure of efficacy, the Delay Interval will be compared between patients whose providers were assigned to the intervention and patients whose providers did not receive the intervention.
|
6 MONTHS
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility/Reach/Adoption
Zeitfenster: 12 months
|
Measurements of intervention delivery include recruitment numbers and provider Participation Rates for enrollment and retention.
The definition of study feasibility consists of provider enrollment rates >= 50%.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Zeitfenster: 12 months
|
Measurements of intervention delivery include the "representativeness" of providers (differences between participants/non-participants).
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Zeitfenster: 12 months
|
Measurements of intervention delivery include the rationale used by clinicians declining participation.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Zeitfenster: 12 months
|
Measurements of intervention delivery include numbers of veterans excluded from the intervention.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Liron Caplan, MD, PhD, Veteran Affairs
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 176843
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .